Patients with a history of anaphylaxis or another severe reaction to IV immune globulin, as well as IgA-deficient individuals with anti-IgA antibodies and a history of IgA hypersensitivity, should not receive this medication [58,59]. The gene discussed is CD79A; the disease is anaphylaxis.